VEGFR3/FLT4 Protein, Human, Recombinant (hFc)

VEGFR3/FLT4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 111.3 kDa and the accession number is P35916-1.

VEGFR3/FLT4 Protein, Human, Recombinant (hFc)

パッケージサイズ	在庫状況	単価(税別)
100 μg	約5 days	￥ 138,000
1 mg	約5 days	￥ 897,500

バルクのお問い合わせ

説明	VEGFR3/FLT4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 111.3 kDa and the accession number is P35916-1.

Species	Human
Expression Host	HEK293 Cells
Tag	C-hFc
Accession Number	P35916-1
別名	FLT41, fms related tyrosine kinase 4, VEGF Receptor 3, PCL, FLT-41, VEGFR-3, LMPH1A, FLT-4, VEGFR3
Construction	extracellular domain (Met 1-Ile 776) of Human VEGFR3 (NP_002011.2)
Protein Purity	> 97 % as determined by SDS-PAGE
分子量	111.3 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

参考文献

1. Shushanov S,et al.(2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52. 2. Iljin K,et al.(2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36. 3. Liu XE,et al.(2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5. 4. Stearns ME,et al.(2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

VEGFR3/FLT4 Protein, Human, Recombinant (hFc)

参考文献

Calculator

技術サポート

Keywords